Arteris delivered the cleanest operating quarter in its recent history. The company posted a non-GAAP loss of $0.02 per share, well ahead of the -$0.05 consensus and the -$0.04 Earnings Whisper number. That was a 50.0% surprise and a 75.0% year-over-year improvement in earnings. Revenue of $25.77 million beat the $24.52 million consensus by 5.1% and grew 48.1%. It also cleared the top of management's own $24-25 million guide. Revenue growth has now accelerated for three straight quarters, from +39% in Q1 to +46% in Q2 to +48% in Q3. Management raised full-year guidance again. The central takeaway is that Arteris is on the verge of non-GAAP profitability. The central tension is that the stock has been treated as though the story were breaking down.
The quality of the beat deserves some scrutiny, because the non-GAAP and GAAP pictures diverge sharply. The non-GAAP operating loss narrowed to $1.2 million from $3.5 million a year ago and from $4.6 million in Q2. Two factors drove that improvement. Non-GAAP gross margin recovered to 89% from 87% in each of the prior two quarters, and non-GAAP operating expenses fell sequentially to $24.0 million after Q2 was inflated by French RSU payroll taxes. On a GAAP basis, however, the net loss widened to $11.2 million, or $0.23 per share, from $9.0 million, or $0.21. Stock-based compensation nearly doubled to $9.2 million, and acquisition amortization rose after the Cycuity deal. The share count also climbed about 15% year over year after a $72 million at-the-market raise, which diluted existing holders even as it lifted cash and investments to roughly $120 million. Gross margin also remains below year-ago levels on both a GAAP and non-GAAP basis, as cost of revenue roughly doubled alongside a new professional-services revenue line.
The demand evidence was strong. ACV plus royalties hit a record $103.8 million, up 39% and above the $99-103 million guide. Trailing-twelve-month royalties rose 71% to $9.4 million, an acceleration from +65% in Q2. That trend is the most important long-term signal, because royalties reflect customer designs actually shipping. Q3 license wins included a top US hyperscaler, two leading semiconductor companies expanding for AI accelerators, and an automotive OEM extending Arteris across successive in-house chip generations. Management said one-third of license dollars came from top-30 global technology companies. On the call, management said chiplets account for about 10% of design starts today and are expected to reach roughly 35% in two to three years at higher ASPs. That positions the new FlexGen and Ncore Multi-Die products as a meaningful mix catalyst.
Bears have legitimate ammunition beneath the beat. Sequential ACV-plus-royalties growth slowed to roughly $4.5 million from about $6.7 million in Q2, which management attributed to deal-timing lumpiness. RPO grew 29% year over year to a record $135.5 million but was roughly flat sequentially. Free cash flow swung to -$2.1 million from +$8.6 million in Q2, blamed on customer payment timing. Year-to-date free cash flow is -$0.9 million, yet the $5-9 million full-year guide was left unchanged for a fourth straight call, which leaves a heavy Q4 collection burden. Q4 revenue guidance of $25.7-26.7 million implies little sequential growth. The exit ACV range of $103-107 million brackets the current level, so its low end would imply no progress. The Q4 non-GAAP operating range of a $0.9 million loss to a $1.1 million profit means a first profitable quarter is likely but not assured. The call also flagged license-assignment risk as physical AI customers are acquired, along with a CFO transition following Saurabh Sinha's arrival in September.
The market setup is more complicated than the surprise implies. Shares closed at $18.10 the day before the report. That was down 42.8% from the $31.67 open after the August release and 27.7% below the 200-day moving average of $25.02. The stock sat just 2.8% above its inter-earnings low of $17.60, set on November 4, and 46.1% below the $33.57 high reached the day after the prior report. Investor sentiment moved the opposite way, rising meaningfully from 0.13 to 0.47. Expectations among engaged investors improved even as the price collapsed. The Earnings Whispers trend readings reflect the same split: sequential growth and momentum are positive, while price and AVWAP trends remain negative.
The bottom line is that Arteris answered the fundamental questions convincingly. Revenue growth is accelerating, royalties are compounding, guidance has risen every quarter this year, and breakeven is within reach. The softer sequential ACV gain, negative quarterly cash flow, flat Q4 revenue outlook, and continued dilution give skeptics enough to argue the easy upside is behind it. With shares near their lows and far below trend, the report shifts the debate to execution. Arteris now needs to show that Q3's ACV slowdown was timing rather than a turn, and to deliver the Q4 cash and profitability the guidance implies.